Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment

• Published in: Blood cancer journal (New York) Vol. 13; no. 1; p. 5
• Main Authors: von Beck, Kelly, von Beck, Troy, Ferrell, P. Brent, Bick, Alexander G., Kishtagari, Ashwin
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 04-01-2023; Springer Nature B.V; Nature Publishing Group
• Subjects: 631/67/68; 692/699/1541/1990; Biomedical and Life Sciences; Biomedicine; Cancer Research; Clonal Hematopoiesis - genetics; Hematologic Diseases; Hematology; Hematopoiesis - genetics; Hematopoietic Stem Cells - pathology; Humans; Mutation; Myeloproliferative Disorders - pathology; Neoplasms; Oncology; Review; Review Article; Stem cells
• ISSN: 2044-5385; 2044-5385
• DOI: 10.1038/s41408-022-00773-8

Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and mCAs that are associated with increased risk of lymphoid malignancy. CH driven by these mutations is termed lymphoid clonal hematopoiesis (L-CH). Unlike myeloid clonal hematopoiesis (M-CH), L-CH has the potential to originate at both stem cells and partially or fully differentiated progeny stages of maturation. In this review, we explore the definition of L-CH in the context of lymphocyte maturation and lymphoid malignancy precursor disorders, the evidence for L-CH in late-onset autoimmunity and immunodeficiency, and the development of therapy-related L-CH following chemotherapy or hematopoietic stem cell transplantation.